TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35381912

Group type: EXPERIMENTAL
Intervention: Tension music
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neutral music
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tension perception
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lower musical tension perception
Number of subjects: 50
Study: 33466233

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr) 20 g/day for 1 week (loading phase) followed by 5 g/day for 7 weeks (maintenance phase)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr)
Number of subjects: 29
Study: 32669145

Group type: EXPERIMENTAL
Intervention: Clozapine and paliperidone palmitate combination therapy
Number of subjects: 50
Study: 35483678

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nebulization 1 mcg/kg in 3 mL of 0.9% saline
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine 1 mcg/kg in 10 mL of 0.9% saline
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous fentanyl 2 mcg/kg in 10 mL of 0.9% saline
Number of subjects: 90
Study: 34562209

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subcostal anterior quadratus lumborum block (QLB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided oblique subcostal transversus abdominis plane block (TAPB)
Number of subjects: 60
Study: 36469484

Group type: EXPERIMENTAL
Intervention: Surgical face mask (FM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No mask (control)
Number of subjects: 16
Study: 34183702

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600-1800 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 49
Study: 32758267

Group type: EXPERIMENTAL
Intervention: Carbon ion reirradiation (reCIRT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intensity-modulated re-radiotherapy (reIMRT)
Number of subjects: 72
Study: 34503349

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily along with 9 cycles of CyBorD
Number of subjects: 140

Group type: COMPARATOR
Intervention: CyBorD alone (control group)
Number of subjects: 140
Study: 32782904

Group type: EXPERIMENTAL
Intervention: Injury Prevention Program (IPP); 30-minute exercise program, 3 times per week for 52 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group; standard operating practice without changes
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Injury Prevention Program (IPP)
Number of subjects: 39
Study: 35261932

Group type: EXPERIMENTAL
Intervention: Combination therapy (sitagliptin + spironolactone)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Sitagliptin add-on
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Spironolactone add-on
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 263
Study: 32560745

Group type: EXPERIMENTAL
Intervention: Standard treatment for COVID-19 + dexamethasone (administered within the first 24 hours)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Standard treatment for COVID-19 + dexamethasone (administered within the first 24 hours for 48-72 hours)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard treatment for COVID-19 (Control Group)
Number of subjects: 105
Study: 33632377

Group type: EXPERIMENTAL
Intervention: Intravenous iron (1000 mg ferric carboxymaltose)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 487
Study: 32430774

Group type: EXPERIMENTAL
Intervention: Full-occlusion biofeedback (BFB) splint
Number of subjects: 41

Group type: COMPARATOR
Intervention: Adjusted occlusal splint (AOS)
Number of subjects: 41
Study: 34477963

Group type: EXPERIMENTAL
Intervention: Refrigerated 2% lignocaine HCl with 1:100,000 epinephrine (LE) after topical ice application for 15 seconds
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional LE infiltration after topical gel application for 1 minute
Number of subjects: 60
Study: 34151843

Group type: EXPERIMENTAL
Intervention: Immune-enhancing nutrition (IMN)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Regular diet and IMN
Number of subjects: 88

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 88
Study: 32516227

Group type: EXPERIMENTAL
Intervention: K-Me [S(+)‐ketamine and methadone]
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0-Mo (placebo and morphine)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0-Me (placebo and methadone)
Number of subjects: 96
Study: 36178335

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily (q.d.)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Vonoprazan 40 mg once daily (q.d.)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily (q.d.)
Number of subjects: 256
Study: 33785490

Group type: EXPERIMENTAL
Intervention: Spesolimab (900 mg intravenous dose)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 33172128

Group type: EXPERIMENTAL
Intervention: Label with a claim present
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Label with a claim absent
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Symbol depicting ‘health’ present
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Participants using NFt
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Participants making decisions implicitly
Number of subjects: 1997
Study: 36066725

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and chemotherapy
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 780
Study: 33153401

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-molecular weight heparin (enoxaparin)
Number of subjects: 100
Study: 32951337

Group type: EXPERIMENTAL
Intervention: Knowledge-based planning (KBP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clinical plan (CL)
Number of subjects: 60
Study: 35437957

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQs) for 1 month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of FQs with cephalosporins/macrolides for 1 month
Number of subjects: 60
Study: 33780544

Group type: EXPERIMENTAL
Intervention: HO-ASE
Number of subjects: 282441

Group type: COMPARATOR
Intervention: Reportable HAIs
Number of subjects: 282441

Group type: EXPERIMENTAL
Intervention: HO-ASE missed by reportable HAIs
Number of subjects: 282441

Group type: COMPARATOR
Intervention: Reportable HAIs missed by HO-ASE
Number of subjects: 282441

Group type: EXPERIMENTAL
Intervention: HO-ASEs
Number of subjects: 282441
Study: 32826158

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg and 30 mg doses)
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Heparin lead-in
Number of subjects: 2680
Study: 35353979

Group type: EXPERIMENTAL
Intervention: Ivermectin (400 µg per kilogram of body weight) once daily for 3 days
Number of subjects: 3515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3515

Group type: EXPERIMENTAL
Intervention: Ivermectin (modified intention-to-treat analysis)
Number of subjects: 3515

Group type: EXPERIMENTAL
Intervention: Ivermectin (per-protocol analysis)
Number of subjects: 3515
Study: 35311524

Group type: EXPERIMENTAL
Intervention: NTM-1633 (0.033, 0.165, or 0.330 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NTM-1633 (0.330 mg/kg)
Number of subjects: 24
Study: 32144522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 20 mg kg-1 IV‐TXA and 20 mg IV‐DXM
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Six doses of IV‐TXA (total dosage > 6 g)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Six doses of IV‐TXA combined with three doses of IV‐DXM (total dosage = 40 mg)
Number of subjects: 125
Study: 35970494

Group type: EXPERIMENTAL
Intervention: Combined myo-inositol, probiotics, and micronutrient supplementation
Number of subjects: 589

Group type: COMPARATOR
Intervention: Standard micronutrient supplement (control)
Number of subjects: 589
Study: 33348420

Group type: EXPERIMENTAL
Intervention: Trilaciclib prior to carboplatin, etoposide and atezolizumab (E/P/A)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo prior to carboplatin, etoposide and atezolizumab (E/P/A)
Number of subjects: 105
Study: 34225321

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise, 3-4 days/week, 25-40 min, 14 ± 1 wk
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard care (Control), n = 28
Number of subjects: 59
Study: 34448003

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study: 36018541

Group type: EXPERIMENTAL
Intervention: Active cryoneurolysis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 16
Study: 33333410

Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) 2 mg continuously
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dydrogesterone (DYG)
Number of subjects: 150
Study: 34533189

Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - 4 points of BTX‐A application (2 U/point) for relaxation of the levator labii superioris alaeque nasi and levator labii superioris muscles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - 2 points of BTX‐A (2 U/point) for relaxation of only the levator labii superioris alaeque nasi muscle
Number of subjects: 0
Study: 32209570

Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel regimen + nintedanib
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Complete interval debulking surgery (IDS)
Number of subjects: 188
Study: 34844929

Group type: EXPERIMENTAL
Intervention: Exercise and education programme
Number of subjects: 206

Group type: COMPARATOR
Intervention: Intra‐articular saline injections
Number of subjects: 206
Study: 36066863

Group type: EXPERIMENTAL
Intervention: Mirror exposure (four sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control (4 weeks waiting period)
Number of subjects: 0
Study: 34190419

Group type: EXPERIMENTAL
Intervention: FDC formulation of bazedoxifene 20 mg and cholecalciferol 8 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Individual component tablets of bazedoxifene and cholecalciferol
Number of subjects: 52
Study: 35404638

Group type: EXPERIMENTAL
Intervention: Moral reconation therapy (MRT)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Moral reconation therapy (MRT) (per-protocol analysis)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Usual care (UC) (per-protocol analysis)
Number of subjects: 341
Study: 33753353

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic variation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heritability estimates
Number of subjects: 0
Study: 32503599

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg
Number of subjects: 7012

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 7012

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg
Number of subjects: 7012

Group type: COMPARATOR
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 7012

Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 7012

Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 7012
Study: 35936982

Group type: EXPERIMENTAL
Intervention: Routine nursing and DEX‐assisted anesthesia (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Comfortable nursing and DEX‐assisted anesthesia (Group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (routine nursing and anesthesia)
Number of subjects: 66
Study: 33740099

Group type: EXPERIMENTAL
Intervention: Non-R132H IDH1/2 mutations
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDH1-R132H mutations
Number of subjects: 0
Study: 32580918

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV) administered in 0, 1, 2, and 3 dose schedules at 6, 10, and 14 weeks of age
Number of subjects: 364
Study: 33952669

Group type: EXPERIMENTAL
Intervention: GMEX rapid point-of-care CYP2C19 genotyping system
Number of subjects: 408

Group type: COMPARATOR
Intervention: YZY Kit (laboratory-based technology)
Number of subjects: 408
Study: 35595376

Group type: EXPERIMENTAL
Intervention: Surrogates of patients with SABI
Number of subjects: 206

Group type: COMPARATOR
Intervention: Surrogates of non-SABI patients
Number of subjects: 206
Study: 32591238

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 34048978

Group type: EXPERIMENTAL
Intervention: Genetically modified hybrid aspens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural accessions of P. tremula
Number of subjects: 0
Study: 35780325

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU of vitamin D3 monthly for 5 years)
Number of subjects: 21315
Study: 34225200

Group type: EXPERIMENTAL
Intervention: Heat stress + ADP group (HSA, basal diet supplemented with 1,000 mg/kg ADP)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Heat stress group (HS, fed basal diet)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Heat stress + ADP group (HSA)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Heat stress group (HS)
Number of subjects: 144
Study: 33080407

Group type: EXPERIMENTAL
Intervention: Transthoracic lung ultrasound at various PEEP levels (4 to 20 cmH2O)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Transthoracic lung ultrasound
Number of subjects: 18
Study: 35476296

Group type: EXPERIMENTAL
Intervention: Paper-and-pencil observation
Number of subjects: 12

Group type: COMPARATOR
Intervention: The Observer XT® desktop software
Number of subjects: 12

Group type: COMPARATOR
Intervention: Big Eye Observer® smartphone application
Number of subjects: 12
Study: 32197853

Group type: EXPERIMENTAL
Intervention: Maternal colostrum (MC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Commercial whey-based colostrum replacer (CR) 150 g of IgG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-quality maternal colostrum (LMC) supplemented with CR (LMC-CR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Commercial whey-based colostrum replacer (CR) 110 g of IgG
Number of subjects: 60
Study: 35549802

Group type: COMPARATOR
Intervention: Thrombopoietin mimetic peptide 0.3 μg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thrombopoietin mimetic peptide 1.0 μg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thrombopoietin mimetic peptide 2.0 μg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33831502

Group type: EXPERIMENTAL
Intervention: Anodic tDCS with balance training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham tDCS with balance training
Number of subjects: 82
Study: 33438234

Group type: EXPERIMENTAL
Intervention: Improvement of EF to >35% at first follow-up
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Return of EF to ≤35% at second follow-up
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Improvement of EF by >10% at first follow-up
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Decrease of EF by >10% at second follow-up
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Normalization of EF (≥55%) at first follow-up
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Comparison of improvement in EF between ischemic and nonischemic cardiomyopathy
Number of subjects: 1178
Study: 32259214

Group type: EXPERIMENTAL
Intervention: Ubrogepant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33978196

Group type: EXPERIMENTAL
Intervention: Chlorine-containing disinfectant and multi-enzyme detergent
Number of subjects: 6

Group type: COMPARATOR
Intervention: Chlorine-containing disinfectant
Number of subjects: 6
Study: 36123934

Group type: EXPERIMENTAL
Intervention: ISU303 (Agalsidase beta), 1 mg/kg dose administered every other week for 6 months
Number of subjects: 10
Study: 34107551

Group type: EXPERIMENTAL
Intervention: VA-dual therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: VAC-triple therapy
Number of subjects: 59
Study: 36232037

Group type: EXPERIMENTAL
Intervention: Teacher incentives (high-value sunglasses worth USD 148, moderate-value eyeglasses worth USD 89, cash incentives USD 35)
Number of subjects: 3401

Group type: COMPARATOR
Intervention: No teacher incentives offered (control group)
Number of subjects: 3401
Study: 34706171

Group type: EXPERIMENTAL
Intervention: Itepekimab (300 mg)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Itepekimab plus dupilumab (both at 300 mg)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Itepekimab
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Itepekimab and Dupilumab monotherapies
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Combination therapy (Itepekimab plus Dupilumab)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: All trial groups
Number of subjects: 296
Study: 36006665

Group type: EXPERIMENTAL
Intervention: WeChat-based life review program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group 1 (friendly visiting)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 150
Study: 34684511

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vitamin D status above 75 nmol/L
Number of subjects: 67
Study: 32434638

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.3 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intramuscular phenobarbital sodium (10 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (phenobarbital sodium)
Number of subjects: 70
Study: 35610711

Group type: EXPERIMENTAL
Intervention: Cognitive remediation training and social recovery focused cognitive behavioural therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32591862

Group type: EXPERIMENTAL
Intervention: TriMixDC-MEL
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (standard follow-up)
Number of subjects: 41
Study: 34859460

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intralesional corticosteroids (ILCS)
Number of subjects: 16
Study: 33403883

Group type: EXPERIMENTAL
Intervention: Finnish Cancer Registry (FCR) data
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Missing CRFs from clinicians
Number of subjects: 1475
Study: 32361863

Group type: EXPERIMENTAL
Intervention: Conventional fractionated standard radiotherapy (CRT)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Short-course radiotherapy (SRT)
Number of subjects: 394
Study: 35527346

Group type: EXPERIMENTAL
Intervention: Radio-guided occult lesion localisation using iodine-125 (125I) seed (ROLLIS)
Number of subjects: 659
Study: 35383463

Group type: EXPERIMENTAL
Intervention: 2 serial NP measurements (BNP or NT-proBNP)
Number of subjects: 5393

Group type: EXPERIMENTAL
Intervention: 2 serial NP measurements (BNP)
Number of subjects: 5393

Group type: EXPERIMENTAL
Intervention: 2 serial NP measurements (NT-proBNP)
Number of subjects: 5393

Group type: EXPERIMENTAL
Intervention: 2 serial NP measurements
Number of subjects: 5393
Study: 36321951

Group type: EXPERIMENTAL
Intervention: TPGS emulsification of berberine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quillaja extract emulsification of berberine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Berberine powder (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TPGS emulsification
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quillaja extract emulsification
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Emulsification (both TPGS and Quillaja)
Number of subjects: 12
Study: 33602433

Group type: EXPERIMENTAL
Intervention: Distal radial access
Number of subjects: 282

Group type: COMPARATOR
Intervention: Proximal radial access
Number of subjects: 282
Study: 32394890

Group type: EXPERIMENTAL
Intervention: Exercise group (40 minutes of supervised aerobic exercise training and 10 minutes of stretching class, 3 times a week for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 35298426

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam plus metronidazole (n = 62)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Meropenem (n = 63)
Number of subjects: 142
Study: 32779386

Group type: EXPERIMENTAL
Intervention: Over-the-counter splint (SOVA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Gold standard bite splint (Michigan)
Number of subjects: 67
Study: 35594284

Group type: EXPERIMENTAL
Intervention: Piperacillin‐tazobactam
Number of subjects: 121

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 121
Study: 33939666

Group type: EXPERIMENTAL
Intervention: Low-dose Auxora plus standard of care (SOC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-dose Auxora plus standard of care (SOC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 21
Study: 33211607

Group type: EXPERIMENTAL
Intervention: TIPS-Plus (provider scripts + patient messages)
Number of subjects: 240

Group type: COMPARATOR
Intervention: TIPS-Basic (provider scripts only)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: TIPS-Plus and TIPS-Basic
Number of subjects: 240
Study: 35078021

Group type: EXPERIMENTAL
Intervention: High-intensity static stretching (HI-SS) intervention group (n = 14; stretch intensity 6–7 out of 10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low-intensity static stretching (LI-SS) intervention group (n = 14; stretch intensity 0–1 out of 10)
Number of subjects: 28